RxTrials Institute Drug Pipeline Alert

Sunesis’ SNS-595 has demonstrated positive interim results in a Phase II study of patients with platinum-resistant ovarian cancer who failed treatment with platinum-containing regimens.

In 31 of 35 patients evaluable for best response, one patient had a complete response, four had partial responses (two unconfirmed) and 26 had stable disease, according to Sunesis.

The candidate was administered once daily every three weeks at 48 mg/m2. The dose has been shown to be safe, and the company said it will increase the dosage level to 60 mg/m2.